tetano
Editor, Senior Moderator
Vaccine. 2019 Nov 1. pii: S0264-410X(19)31460-4. doi: 10.1016/j.vaccine.2019.10.071. [Epub ahead of print] [h=1]End of season influenza vaccine effectiveness in primary care in adults and children in the United Kingdom in 2018/19.[/h]
Pebody RG[SUP]1[/SUP], Whitaker H[SUP]2[/SUP], Ellis J[SUP]2[/SUP], Andrews N[SUP]2[/SUP], Marques DFP[SUP]3[/SUP], Cottrell S[SUP]4[/SUP], Reynolds AJ[SUP]3[/SUP], Gunson R[SUP]5[/SUP], Thompson C[SUP]2[/SUP], Galiano M[SUP]2[/SUP], Lackenby A[SUP]2[/SUP], Robertson C[SUP]6[/SUP], O'Doherty MG[SUP]7[/SUP], Owens K[SUP]2[/SUP], Yonova I[SUP]8[/SUP], Shepherd SJ[SUP]5[/SUP], Moore C[SUP]4[/SUP], Johnston J[SUP]7[/SUP], Donati M[SUP]9[/SUP], McMenamin J[SUP]3[/SUP], Lusignan S[SUP]10[/SUP], Zambon M[SUP]2[/SUP].
[h=3]Author information[/h] 1 Public Health England, London, United Kingdom. Electronic address: Richard.Pebody@phe.gov.uk. 2 Public Health England, London, United Kingdom. 3 Health Protection Scotland, Glasgow, United Kingdom. 4 Public Health Wales, Cardiff, United Kingdom. 5 West of Scotland Specialist Virology Centre, Glasgow, United Kingdom. 6 University of Strathclyde, Glasgow, United Kingdom. 7 Public Health Agency Northern Ireland, Belfast, United Kingdom. 8 University of Surrey Guildford, United Kingdom; Royal College of General Practitioners Research and Surveillance Centre, London, United Kingdom. 9 Public Health England, Bristol, United Kingdom. 10 Royal College of General Practitioners Research and Surveillance Centre, London, United Kingdom; Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, United Kingdom.
[h=3]Abstract[/h] 2018/19 was the first season of introduction of a newly licensed adjuvanted influenza vaccine (aTIV) for adults aged 65 years and over and the sixth season in the roll-out of a childhood influenza vaccination programme with a quadrivalent live attenuated influenza vaccine (LAIV). The season saw mainly A(H1N1)pdm09 and latterly A(H3N2) circulation. End-of-season adjusted vaccine effectiveness (aVE) estimates against laboratory confirmed influenza infection in primary care were calculated using the test negative case control method adjusting for key confounders. End-of-season aVE was 44.3% (95% CI: 26.8, 57.7) against all laboratory-confirmed influenza; 45.7% (95% CI: 26.0, 60.1) against influenza A(H1N1)pdm09 and 35.1% (95% CI: -3.7,59.3) against A(H3N2). Overall aVE was 49.9% (95%CI: -13.7, 77.9) for all those ≥ 65 years of age and 62.0% (95% CI: 3.4, 85.0) for those who received aTIV. Overall aVE for 2-17 year olds receiving LAIV was 48.6% (95% CI: -4.4, 74.7). The paper provides evidence of overall significant influenza VE in 2018/19, most notably against influenza A(H1N1)pdm09, however, as seen in 2017/18, there was reduced, non-significant VE against A(H3N2). aTIV provided significant protection for those 65 years of age and over.
Crown Copyright ? 2019. Published by Elsevier Ltd. All rights reserved.
[h=4]KEYWORDS:[/h] Effectiveness; Influenza; Primary care; Vaccine
PMID: 31685296 DOI: 10.1016/j.vaccine.2019.10.071
Pebody RG[SUP]1[/SUP], Whitaker H[SUP]2[/SUP], Ellis J[SUP]2[/SUP], Andrews N[SUP]2[/SUP], Marques DFP[SUP]3[/SUP], Cottrell S[SUP]4[/SUP], Reynolds AJ[SUP]3[/SUP], Gunson R[SUP]5[/SUP], Thompson C[SUP]2[/SUP], Galiano M[SUP]2[/SUP], Lackenby A[SUP]2[/SUP], Robertson C[SUP]6[/SUP], O'Doherty MG[SUP]7[/SUP], Owens K[SUP]2[/SUP], Yonova I[SUP]8[/SUP], Shepherd SJ[SUP]5[/SUP], Moore C[SUP]4[/SUP], Johnston J[SUP]7[/SUP], Donati M[SUP]9[/SUP], McMenamin J[SUP]3[/SUP], Lusignan S[SUP]10[/SUP], Zambon M[SUP]2[/SUP].
[h=3]Author information[/h] 1 Public Health England, London, United Kingdom. Electronic address: Richard.Pebody@phe.gov.uk. 2 Public Health England, London, United Kingdom. 3 Health Protection Scotland, Glasgow, United Kingdom. 4 Public Health Wales, Cardiff, United Kingdom. 5 West of Scotland Specialist Virology Centre, Glasgow, United Kingdom. 6 University of Strathclyde, Glasgow, United Kingdom. 7 Public Health Agency Northern Ireland, Belfast, United Kingdom. 8 University of Surrey Guildford, United Kingdom; Royal College of General Practitioners Research and Surveillance Centre, London, United Kingdom. 9 Public Health England, Bristol, United Kingdom. 10 Royal College of General Practitioners Research and Surveillance Centre, London, United Kingdom; Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, United Kingdom.
[h=3]Abstract[/h] 2018/19 was the first season of introduction of a newly licensed adjuvanted influenza vaccine (aTIV) for adults aged 65 years and over and the sixth season in the roll-out of a childhood influenza vaccination programme with a quadrivalent live attenuated influenza vaccine (LAIV). The season saw mainly A(H1N1)pdm09 and latterly A(H3N2) circulation. End-of-season adjusted vaccine effectiveness (aVE) estimates against laboratory confirmed influenza infection in primary care were calculated using the test negative case control method adjusting for key confounders. End-of-season aVE was 44.3% (95% CI: 26.8, 57.7) against all laboratory-confirmed influenza; 45.7% (95% CI: 26.0, 60.1) against influenza A(H1N1)pdm09 and 35.1% (95% CI: -3.7,59.3) against A(H3N2). Overall aVE was 49.9% (95%CI: -13.7, 77.9) for all those ≥ 65 years of age and 62.0% (95% CI: 3.4, 85.0) for those who received aTIV. Overall aVE for 2-17 year olds receiving LAIV was 48.6% (95% CI: -4.4, 74.7). The paper provides evidence of overall significant influenza VE in 2018/19, most notably against influenza A(H1N1)pdm09, however, as seen in 2017/18, there was reduced, non-significant VE against A(H3N2). aTIV provided significant protection for those 65 years of age and over.
Crown Copyright ? 2019. Published by Elsevier Ltd. All rights reserved.
[h=4]KEYWORDS:[/h] Effectiveness; Influenza; Primary care; Vaccine
PMID: 31685296 DOI: 10.1016/j.vaccine.2019.10.071